Why Entrada Therapeutics, Inc.’s (TRDA) Stock Is Up 5.68%
As of Tuesday, September 08, Entrada Therapeutics, Inc.’s TRDA share price has surged by 5.68%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Entrada Therapeutics, Inc.’s (TRDA) Stock Is Down 5.77%
As of Wednesday, August 26, Entrada Therapeutics, Inc.’s TRDA share price has dipped by 5.77%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Is Entrada Therapeutics, Inc. (TRDA) Overvalued?
We dive into why Entrada Therapeutics, Inc. (TRDA) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Entrada Therapeutics, Inc.’s (TRDA) Stock Is Up 5.50%
As of Wednesday, August 19, Entrada Therapeutics, Inc.’s TRDA share price has surged by 5.50%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
What You Need to Know About Entrada Therapeutics, Inc.'s Q3 Earnings
Entrada Therapeutics, Inc.'s fiscal Q3 earnings report was released on Wednesday, August 05. Let's dive in to see if (TRDA) missed or beat analyst's expectations.Tudor Pop
Financial Summary
| Share Statistics | TRDA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $271.1 | $284.4 | 30% |
|
| Shares Out (Mil) | 42.2 | 54.1 | 44% |
|
| Institutional Ownership | 96.7% | 92.9% | 71% |
|
| Float (Mil) | 19.8 | 42.2 | 28% |
|
| Beta | -0.26 | 0.95 | 3% |
|
| Avg Daily Volume (000s) | 307 | 463 | 52% |
|
| Price Change (52-week) |
42.2% | 59.0% | 78% |
|
| Growth | TRDA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (40.2%) | (10.1%) | 9% |
|
| EPS (5yr) | 32.1% | 15.5% | 83 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.6%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 6 | 6 | |
| Current EPS | ($0.980) | ($3.702) | ($2.978) | |
| Month Ago EPS | ($0.834) | ($3.715) | ($3.284) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.939) | ($3.794) | ($3.257) | |
| Year/Year Chg | (3.3%) | 6.5% | (14.7%) | |
| Financials | TRDA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $37 | 6% |
|
| Net Income (TTM) (Mil) | ($166) | ($43) | 8% |
|
| EPS (TTM) | ($3.968) | ($1.500) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($135) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $26 | $2 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $44 | $4 | 38% |
|
| Enterprise Value (Q1) (Mil) | $73 | $190 | 19% |
|
| Valuation | TRDA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.16 | 2.79 | 27% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TRDA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (44.3%) | (47.8%) | 13% |
|
| ROE | (54.1%) | (55.3%) | 15% |
|
| Liabilities to Assets | 21.9% | 29.8% | 14% |
|
| F-Score | 1 | 3 | 1% |
|
Entrada Therapeutics, Inc. did not pass any screens on 9/8/2026.
